PREMENSTRUAL SYNDROME: CLINICAL PATTERN, DIAGNOSTICS AND THERAPEUTIC APPROACHES
https://doi.org/10.21518/2079-701X-2017-2-106-111
Abstract
Premenstrual syndrome (PMS) is a complex, cyclical, polyethiological, multifactorial combination of physical and mental disorders that occur in some women of reproductive age in the second - luteal - phase of the menstrual cycle and negatively affect the woman’s usual lifestyle.
Premenstrual dysphoric disorder (PMDD) is a severe form of PMS in which psychoneurological symptoms prevail. For the diagnosis of PMDD, the specific DSM-5 criteria were developed by the American Psychiatric Association according to which the the diagnosis is confirmed by the presence of five or more symptoms in women during the week prior to menstruation and their disappearance a few days after the onset of menstruation. These symptoms are observed for at least two cycles.
Treatment of women with PMS/PMDD, first of all, should start with the lifestyle adjustment, inclusion of regular mode rate physical activity into daily activities. The effectiveness of vitamins B6, E and calcium has not been confirmed in studies. First-line drug therapy includes SSRIs or combined oral contraceptives containing drospirenone are prescribed first, then agonists of gonadotropin-releasing hormone.
About the Authors
L. P. Guliyeva
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
S. V. Yureneva
Scientific Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov
Russian Federation
MD
Russian Federation
MD
References
1. Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry, 2012, 69: 300.
2. Halbreich U, Backstrom T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol, 2007, 23: 123.
3. Freeman EW, Halberstadt SM, Rickels K, et al. Core symptoms that discriminate premenstrual syndrome. J Womens Health (Larchmt), 2011, 20: 29.
4. Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord, 2005, 85: 275.
5. Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol, 1990, 76: 302.
6. Casper RF, Graves GR, Reid RL. Objective measurement of hot flushes associated with the premenstrual syndrome. Fertil Steril, 1987, 47: 341.
7. Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res, 2009, 9: 157.
8. Di Giulio G, Reissing ED. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J Psychosom Obstet Gynaecol, 2006, 27: 201.
9. Freeman EW, Sammel MD, Rinaudo PJ, Sheng L. Premenstrual syndrome as a predictor of menopausal symptoms. Obstet Gynecol, 2004, 103: 960.
10. O’Brien PMS, Bä ckströ m T, Brown C, Dennerstein L, Endicott J et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Mon-treal consensus. Arch Womens Ment Health, 2011, 14: 13-21.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, 2013.
12. Goodale IL, Domar AD, Benson H. Alleviation of premenstrual syndrome symptoms with the relaxation response. Obstet Gynecol, 1990, 75: 649.
13. Steege JF, Blumenthal JA. The effects of aerobic exercise on premenstrual symptoms in middleaged women: a preliminary study. J Psychosom Res, 1993, 37: 127.
14. Aganoff JA, Boyle GJ. Aerobic exercise, mood states and menstrual cycle symptoms. J Psychosom Res, 1994, 38: 183.
15. Stewart A. Vitamin B6 in the treatment of the premenstrual syndrome–review. Br J Obstet Gynecol, 1991, 98: 329.
16. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol, 1998, 179: 444.
17. Facchinetti F, Borella P, Sances G, et al. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol, 1991, 78: 177.
18. Walker AF, De Souza MC, Vickers MF, et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health, 1998, 7: 1157.
19. London RS, Murphy L, Kitlowski KE, Reynolds MA. Efficacy of alpha-tocopherol in the treatment of the premenstrual syndrome. J Reprod Med, 1987, 32: 400.
20. Wyatt KM, Dimmock PW, Jones PW, Shaughn O’Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ, 1999, 318: 1375.
21. Bertone-Johnson ER, Hankinson SE, Bendich A et al. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med, 2005, 165: 1246.
22. Stone, AB, Pearlstein, TB, Brown, WA. Fluoxetine in the treatment of premenstrual syndrome. Psychopharm Bull, 1991, 26: 331.
23. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry, 1991, 52: 290.
24. Wood SH, Mortola JF, Chan YF, et al. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol, 1992, 80: 339.
25. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Cana dian Fluoxetine/Premenstrual Dysphoria Colla bo ra tive Study Group. N Engl J Med, 1995, 332: 1529.
26. Marjoribanks J, Brown J, O’Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev, 2013, 6: CD001396.
27. Yonkers KA, Halbreich U, Freeman E, et al. Sympto matic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA, 1997, 278: 983.
28. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry, 1999, 56: 932.
29. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology, 1995, 12: 167.
30. Brown J, O’ Brien PM, Marjoribanks J, Wyatt K. Selec tive serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev, 2009: CD001396.
31. Wikander I, Sundblad C, Andersch B, et al. Citalo pram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol, 1998, 18: 390.
32. Freeman EW. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs 2004; 18:453.
33. Shah NR, Jones JB, Aperi J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol, 2008, 111: 1175.
34. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol, 2005, 106: 492.
35. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception, 2005, 72: 414.
36. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for
37. premenstrual syndrome. Cochrane Database Syst Rev, 2009: CD006586.
38. Lazarou Ch, Kapsou M. The role of folic acid in prevention and treatment of depression: An overview of existing evidence and implications for practice. Complementary Therapies in Clinical Practice 2010;16:161–166
39. According to the data provided by most studies so far, it seems that, 15–38% of adults who have been diagnosed with severe depression, have also. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev Altern Med Rev 2008;13(3):216–26
40. Beydoun MA, Shroff MR, Beydoun HA, Zonderman AB. Serum folate, vitamin B-12, and homocysteine and their association with depressive symptoms among U.S. adults. Psychosom Med. 2010 Nov;72(9):862-73
41. Shuaibi AM, House JD, Sevenhuysen G P. Folate Status of Young Canadian Women after Folic Acid Fortification of Grain Products. J Am Diet Assoc 2008;108(12): 2090–4
42. Klipping C, Duijkers I, Fortier MP et al. Contraceptive efficacy and tolerability of ethinylestradiol 20 mg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicenter, randomized, controlled study. J Fam Plann Reproad Health Care, 2012, 38: 73-83.
43. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab, 1991, 72: 252A.
44. Mezrow G, Shoupe D, Spicer D, et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril, 1994, 62: 932.
45. Wyatt KM, Dimmock PW, Ismail KM, et al. The effectiveness of GnRHa with and without ‘addback’ therapy in treating premenstrual syndrome: a meta analysis. BJOG, 2004, 111: 585.
Review
For citations:
Guliyeva LP, Yureneva SV. PREMENSTRUAL SYNDROME: CLINICAL PATTERN, DIAGNOSTICS AND THERAPEUTIC APPROACHES. Meditsinskiy sovet = Medical Council. 2017;(2):106-111. (In Russ.) https://doi.org/10.21518/2079-701X-2017-2-106-111
Views:
1233
Email this article 